宜明昂科-B(01541.HK)今日盘中大涨5.43%,股价异动引起市场广泛关注。
据相关披露,公司自主研发的一种联合化疗方案IMM2510,旨在用于非小细胞肺癌(NSCLC)一线治疗,已完成了Ib/II期临床试验首例患者的给药。在完成安全性导入期后,公司将在上述临床中招募更多一线患者,并计划在2025年下半年发布初步临床数据。
这一进展表明宜明昂科在研发创新药物、为肺癌患者提供新的治疗方案方面取得了重要进展,未来有望推出具有疗效的肺癌新药。由于临床前景向好,投资者对公司发展前景抱有信心,因此推动了今日股价大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.